Octagon Capital Advisors LP Cyma Bay Therapeutics, Inc. Transaction History

Octagon Capital Advisors LP

  • $414 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$12.63 - $24.47 $24 Million - $46.4 Million
-1,897,168 Reduced 41.51%
2,673,750 $63.2 Million
Q1 2023

May 15, 2023
BUY
$5.88 - $9.59 $15.9 Million - $26 Million
2,711,718 Added 145.85%
4,570,918 $39.9 Million
Q4 2022

Feb 14, 2023
BUY
$3.22 - $6.27 $5.99 Million - $11.7 Million
1,859,200 New
1,859,200 $11.7 Million

Others Institutions Holding CBAY

# of Institutions
6
Shares Held
1.82M
Call Options Held
0
Put Options Held
0
View Full List

About CymaBay Therapeutics, Inc.

CBAY Quotes by TradingView
  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email